LabisiaLife

23/01/2025

LABEESITY SKF7® has SOLD OUT!

Clinically tested to effectively target and reduce abdominal fat, this breakthrough solution will make its highly anticipated return in March 2025.

Explore the science behind it here: https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.15229

Thank you for your continued support.

for enquiries : https://wbit.ly/Labeesity

14/12/2024

People have found out about Labeesity SKF7 and everyday we have enquiries and orders from customers.

For those who want to maintain a healthy metabolism and stay healthy, you can try it now 😎

And if you are a General Practitioner or Pharmacist who is interested to know more about Labeesity SKF7, please do not hesitate to email or WhatsApp us at: https://bit.ly/Labeesity

SKF7 is the first in Malaysia that has been approved by the FDA . For more details about SKF7 you can click on this link (clinical results) : https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15229 -bib-0013

08/11/2024

🎉🎉🎉

Akan datang Labeesity SKF7 akan masuk pasaran IRAQ - Alhamdullilah

Jika berminat nak tahu kelebihan Labeesity SKF7, boleh baca (ujian klinikal) di sini : https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15229 -bib-0013

Untuk sebarang pertanyaan boleh WhatsApp kami : https://bit.ly/Labeesity

04/11/2024

😍

Message from Dr Kenna from USA who is interested to promote Labeesity SKF7 to her patients

For Dr. Kenna's details visit this link https://lnkd.in/gA_MzKkA

Info:
US FDA recognized that SKF7 is safe for a dietary daily intake of 750 mg.

23/10/2024

Congratulations! Received good news from Medika Natura. Their business has penetrated the Saudi Arabian market. Alhamdullilah

17/10/2024

Congratulations. Another achievement for Medika Natura 🎊

***
This Memorandum of Agreement (MoA) establishes a collaboration between Medika Natura Sdn Bhd and the University of Malaya (UM) for a research project focused on Ischemic Heart Disease (IHD) and Sarcopenia. The project is supported by the Strategic Research Fund from the Academy of Sciences Malaysia (ASM) and the Ministry of Science, Technology, and Innovation (MOSTI), with Medika Natura contributing co-investment to drive the research towards clinical applications. This partnership aims to advance understanding and develop solutions for these significant health issues, with a focus on translating research findings into practical healthcare innovations.

15/10/2024

Exciting news from Medika Natura 😍

***

After months of meticulous negotiation and preparation with our counterparts in the European Union, Medika Natura Sdn Bhd is proud to announce a significant milestone: our products are now heading to the Euro-Asian region for registration. This marks an important step in our unwavering commitment to bringing clinically validated, high-quality, natural health solutions to a broader global market.

Through strategic collaboration and tireless dedication, Medika Natura® has laid the groundwork for this expansion, ensuring that our cutting-edge botanical formulations, including the flagship SKF7®, will soon be accessible to new populations in need of safe, clinically proven health solutions. This move underscores our mission to bridge the gap between natural innovation and scientifically and clinically validated wellness, reinforcing Medika Natura®'s position as a leader in botanical therapeutics.

Our team's relentless focus on regulatory excellence and clinical product efficacy has been the driving force behind this breakthrough, allowing us to navigate the complexities of entering new markets.

We are excited to take this next step, continuing to deliver on our promise to provide natural, clinically backed health products that make a meaningful impact on people's lives, as we expand our reach into the Euro-Asian region.

08/10/2024

- received great news from Medika Natura -

Dear Colleagues and Partners,
We are delighted to announce a significant milestone in the engagement between Medika Natura Sdn Bhd and Universiti Malaya (UM). Both organizations will be signing a Memorandum of Agreement (MoA) to formalize our collaboration on PERVIRA® Clinical Research, which focuses on complications related to Ischemic Heart Disease (IHD). This partnership represents an important step towards advancing clinical research and driving healthcare innovation in Malaysia.

PERVIRA®, a pharma-grade formulation derived from Kaempferia parviflora, is widely recognized for its health benefits, including anti-inflammatory, metabolic, and cardiovascular effects. The primary bioactive compound in PERVIRA®, 5,7-Dimethoxyflavone (DMF), has gained attention for its multi-faceted role in enhancing muscle protein synthesis, improving mitochondrial function, and reducing inflammation—key factors implicated in the pathogenesis of IHD.

The signing ceremony will take place during the Selangor Life Sciences Convention 2024, from October 16 to 19, 2024, at the Kuala Lumpur Convention Center (KLCC). This prestigious event will gather leaders from both industry and academia, providing a platform to explore new opportunities for engagement in the life sciences sector. Details of the MoA Signing Ceremony: Date: October 17, 2024 (Thursday) Time: 11:30 AM to 12:30 PM Venue: Exhibitor Stage, Exhibition Hall 6C, Level 1, KLCC Convention Center, Kuala Lumpur In addition, Universiti Malaya will host a pavilion at the event, offering attendees an in-depth look at the university's ongoing research and development initiatives in partnership with industry leaders.

We warmly invite you to join us for this momentous occasion, celebrating an engagement that will help advance clinical research for improved healthcare outcomes in the region.

*********************************

1. Universiti Malaya (UM) is one of the top public universities in Kuala Lumpur, Malaysia. It is ranked #60 in QS World University Rankings 2025. 2. Medika Natura is a leading biopharma company specializing in natural-based life sciences. It is known for developing innovative products that promote health and well-being, with a strong emphasis on rigorous scientific research and development.

13/09/2024

Alhamdullilah. Received great news from France. Now Medika Natura's products goes global.

Korea ✅
Germany ✅
And next is France ✅

All the best! 🥳

🇫🇷

🇲🇾

12/09/2024

First in Malaysia! 🥳

Heartfelt congratulations to Dr. Mohd Ridzuan Mohd Abd Razak and the esteemed team from the Herbal Medicine Research Centre, Institute for Medical Research (IMR), National Institutes of Health, Ministry of Health Malaysia, Shah Alam, under the exemplary leadership of Director Dr. Ami Fazlin Syed Mohamed.

We are proud to celebrate our fruitful strategic research partnership with IMR, which has achieved a significant milestone. For the first time in Malaysia, your groundbreaking article titled "In vitro study on the efficacy of SKF7®️, a Malaysian medicinal plant product against SARS-CoV-2," has been published in the prestigious peer-reviewed journal, BMC Complementary Medicine and Therapies.

This important research not only addresses the urgent challenges posed by the COVID-19 pandemic—such as emerging variants, Long COVID, and healthcare system strain—but also opens the door to further exploration into potential treatments for communicable diseases. Moreover, this work paves the way for Medika Natura Sdn Bhd to conduct more research on the efficacy of SKF7®️ in treating both infectious and non-infectious diseases.

We invite researchers, professionals, and the public to read and engage with this pivotal work, which promises to inspire continued innovation and discovery in the fight against communicable diseases.

Background In early 2020, COVID-19 pandemic has mobilized researchers in finding new remedies including repurposing of medicinal plant products focusing on direct-acting antiviral and host-directed therapies. In this study, we performed an in vitro investigation on the standardized Marantodes pumilu...

10/09/2024

📢

The upcoming plenary session at the National Biotechnology Symposium 2024, organized by the National Institutes of Biotechnology Malaysia, will feature Mr. Abdul Razak Mohd Isa from Medika Natura Sdn Bhd . He will deliver a presentation titled "Decoding the Therapeutic Landscape of SKF7® Phytochemicals: From Molecular Analysis to Disease Management Strategies."

His talk will cover the foundation of the molecular characteristics of SKF7® phytochemicals and their therapeutic potential in disease management, emphasizing how these natural compounds offer innovative and integrated approaches to modern healthcare. The presentation will highlight how scientific advancements applied by Medika Natura have transformed traditional remedies into clinically validated treatments. These developments have challenged outdated perceptions and paved the way for greater acceptance of botanical medicine in therapeutic strategies. With the application of genomics, proteomics, and metabolomics, these natural compounds are now understood at the molecular level, further strengthening their credibility and supporting their integration into contemporary healthcare practices.

Following the plenary, he will participate in a forum titled "Concerted Efforts in Bringing Traditional Medicine with Therapeutic Claims into the Malaysian Healthcare Ecosystem." This panel brings together a distinguished group of experts, including regulators, clinicians, scientists, and researchers from the National Pharmaceutical Regulatory Agency (NPRA), the Institute for Medical Research (IMR), and Universiti Kebangsaan Malaysia (UKM). Among the panelists are Dr. Ami Fazlin binti Syed Mohamed, Prof. Dr. Syarul Nataqain Baharum, Dr. Wan Najbah Nik Nabil, and Prof. Dr. Nor Fadilah Bt. Rajab. They will discuss collaborative efforts to integrate traditional medicine, particularly botanical medicines with therapeutic claims, into the Malaysian healthcare system.

To know more and participate at NBS2024, visit:

About Us Join us at our upcoming scientific symposium, where leading experts from diverse fields will convene to discuss cutting-edge […]

09/09/2024

🎉🎉🎉

" We would like to express our sincere gratitude to Prof. Dr. Rofina Yasmin Othman, Chairman of MRANTI for highlighting Medika Natura Sdn Bhd’s journey towards becoming a leading biopharma company in botanical drug research and commercialization during her keynote address at the International Conference on Natural Products 2024 (ICNP 2024).

Her support and recognition of our efforts are deeply appreciated.

Additionally, we extend our thanks to the participants who contributed by sharing these photos with us.

For more information about the conference, please visit https://lnkd.in/gXgVY7tW "

😊